found that while thoracic compliance is reduced in ALS patients presenting with hypoventilation, inspiratory pressure support can improve compliance [16]. Based on this finding they suggested that NIV may provide nocturnal rest for

fatigued respiratory muscles, thereby increasing selleck chem FTY720 survival rates by improving daytime functioning of respiratory muscles [12]. However, other studies considering Inhibitors,research,lifescience,medical the impact of NIV on ALS patients were retrospective in nature [12,17] and therefore their conclusions as to possible mechanisms by which NIV might improve survival outcomes are unconfirmed. This study has some limitations. Its analysis was performed retrospectively in a relatively small patient population. The mechanisms by which NIV improved survival outcomes in Group 2 are unclear. Inhibitors,research,lifescience,medical Theoretically, improved survival may have been at least partly due to slight but statistically insignificant difference in the frequency of bulbar symptoms between the NIV users and non-users. There is compelling evidence demonstrating that survival is poorest in ALS patients with severe bulbar symptoms [10]. Poor survival may also Inhibitors,research,lifescience,medical be due to poor compliance with NIV therapy. This likely to be a contributing factor also in the present study because

many Group 2 patients with bulbar dysfunction did not tolerate NIV. The results of this study should therefore be confirmed by studying a larger patient cohort and, using a prospective study design. However, mainly because of the fact that NIV has been established as a palliative method of choice for ALS, the ethical

considerations for withholding treatment should be taken seriously into account in any future prospective studies. Second, all patients were referred for evaluation after a diagnosis of ALS was Inhibitors,research,lifescience,medical confirmed. Inhibitors,research,lifescience,medical It was therefore not possible to assess the ventilatory function of patients in the early stage of the disease, preventing us from assessing the possible impact of early NIV initiation on survival outcomes. In addition, most of this study’s patients gave consent for NIV trial in at a later stage of the disease and presented a pCO2 greater Dacomitinib than 6.0 kPa, even if NIV was recommended for these patients in line with current guidelines [4-7]. It is therefore possible that this study failed to show that the initiation of NIV would have had a beneficial effect on the survival in younger NIV patients because the initiation of NIV was decided by the patient. Factors other than NIV may also have had an effect on patient survival. These include treatment with PEG or riluzole, and gender. In addition, the incidence of hypertension and other cardiovascular diseases, decline in pulmonary function as well and whole body function may have impacted patients’ survival outcomes. PEG use may increase survival by months [18]. The same is true also for riluzole, the efficacy of which has been demonstrated in randomized controlled trials [8,9].